Aceragen, Inc. Stock Nyse
Equities
ACGN
US00445F1093
Biotechnology & Medical Research
Financials (USD)
Sales 2021 | - | Sales 2022 | 4.86M | Capitalization | 3.12M |
---|---|---|---|---|---|
Net income 2021 | 98M | Net income 2022 | -23M | EV / Sales 2021 * | - |
Net cash position 2021 * | - | Net cash position 2022 * | - | EV / Sales 2022 * | - |
P/E ratio 2021 * |
-
| P/E ratio 2022 * |
-
| Employees | 26 |
Yield 2021 * |
-
| Yield 2022 * |
-
| Free-Float | 38.12% |
1st Jan change | Capi. | |
---|---|---|
+4.09% | 43.84B | |
+47.81% | 41.25B | |
+9.45% | 41.68B | |
-10.92% | 27.04B | |
+9.32% | 25.53B | |
-24.87% | 18.18B | |
+29.70% | 12.29B | |
+1.28% | 12.29B | |
+7.78% | 11.15B |